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There are few genes that are specific and diagnostic for human herpesvirus-6. U83 and U22 are two of them. U22 is unique,
whereas U83 encodes distant similarity with some cellular chemokines. Reverse transcription-polymerase chain reaction,
cDNA cloning, and sequence analyses show polyadenylated RNA transcripts corresponding to minor full-length and
abundant spliced forms of U83 in human herpesvirus 6-infected cells. The splice donor and acceptor sites do not fit
consensus sequences for either major GT-AG or minor AT-AC introns. However, the spliced form can also be detected in a
U83 transfected cell line; thus the novel sites are used by cellular mechanisms. This intron may represent a new minor CT-AC
splicing class. The novel splicing regulates gene expression by introducing a central stop codon that abrogates production
of the chemokine-like molecule, resulting in an encoded truncated peptide. The use of metabolic inhibitors and an infection
time course showed expression of the two RNA transcripts with immediate early kinetics. However, the full-length product
accumulated later, dependent on virus DNA replication, similar to U22. Sequence analyses of 16 strains showed high
variation (13%) in U83 , with conservation of the novel splice sites. Representative strain variants had similar kinetics of
expression and spliced products. © 1999 Academic Press
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The prevalence of human herpesvirus 6 (HHV-6) is
idespread, and it is one of the more recently identified
uman herpesviruses. Herpesviruses cause persistent/
atent infections for the lifetime of the host and can
eactivate during immunosuppression to cause disease.
HV-6 is a large double-stranded (ds)DNA virus (159 kb)
ncoding more than 100 genes; it is closely related to
uman herpesvirus 7 (HHV-7) and shares genomic sim-
larity with other betaherpesviruses, like human cyto-
egalovirus (HCMV) (Gompels et al., 1995; Nicholas,
996). HHV-6 and HHV-7 cause pediatric febrile illness
ith occasional severe or fatal complications (Asano et
l., 1990, 1992; Hall et al., 1994; Portolani et al., 1997). In
mmunocompromised patients such as transplant or
IDS patients, the viruses can reactivate; here the better-
efined HHV-6 is associated with more severe disease,
ncluding bone marrow suppression and encephalitis
Asano et al., 1990, 1992; Drobyski et al., 1993, 1994; Hall
t al., 1994; Knox et al., 1995; Wang et al., 1996; Portolani
t al., 1997). A link with multiple sclerosis has been
uggested (Challoner et al., 1995; Soldan et al., 1997).
ogether with human immunodeficiency virus (HIV),
HV-6 and HHV-7 have a cellular tropism for CD41 T
1 To whom reprint requests should be addressed at Keppel St.
1-mail: ugompels@hgmp.mrc.ac.uk.
139ymphocytes, which they infect and kill via cell fusion and
ysis (Takahashi et al., 1989; Lusso et al., 1994). There is
ome evidence for interaction between these viruses in
ytic or reactivating latent infections in vitro. In vivo, most
vidence indicates HHV-6, including disseminated and
atal infections in HIV/AIDS patients, as well as a possi-
le factor in their progression (Emery et al., 1999; Knox
nd Carrigan, 1994, 1996).
Herpesvirus gene expression is tightly regulated dur-
ng lytic and latent infections. Limited data suggest this
lso applies to HHV-6. In latent infections, there is little
irus gene expression, whereas in lytic infections, there
s a cascade of expression from immediate-early (IE) to
arly to late times postinfection (p.i.). IE genes require no
rior virus gene expression, whereas late genes require
oth virus gene expression and DNA replication (Miran-
ola et al., 1998). At least one IE gene, Rep or U94,
ppears to also be expressed during in vitro or in vivo
atent infections and shows suppression of virus DNA
eplication (Rotola et al., 1998; S. Turner, D. DiLuca, and
. A. Gompels, unpublished results). In general, herpes-
iruses have relatively few spliced genes compared with
he host cell, and spliced genes usually are either rare
atent genes or of the IE kinetic class with genes ex-
ressed later under virus gene regulation usually lacking
plicing. However, much of these data relate to herpes
implex virus type 1 (HSV1) or HCMV (Mocarski et al.,
990; Wagner et al., 1995; Meier and Stinski, 1996). Little
0042-6822/99 $30.00
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140 FRENCH ET AL.s known about regulation in HHV-6, and preliminary data
how up-regulation of the cell cycle rather than the host
ell shutoff as observed in HSV1 (Black et al., 1991).
ecently, complex patterns of splicing have been docu-
ented in HHV-6-infected cells in both IE and late tran-
cripts, which suggests there may be control of splicing
r splicing efficiency that may be different from that of the
ther herpesviruses (Mirandola et al., 1998). Compari-
ons of complete genomic sequences of different HHV-7
trains with HHV-6 and HCMV suggest there may be
ore splicing in these betaherpesviruses than currently
ecognised (Gompels et al., 1995; Megaw et al., 1998). To
ate, splicing observed in herpesviruses, including those
eported for HHV-6, conform to the major splice class as
epresented in spliced gene catalogues (Mount, 1982;
tephens and Schneider, 1992). Here we investigate ex-
ression and aberrant splicing of genes specific to
HV-6.
Most HHV-6 genes have homologues in the closely
elated HHV-7, but a few are specific and diagnostic for
HV-6 infections. One gene is U22, which encodes a
pecific glycoprotein unique to HHV-6. Another specific
ene is U83, which was identified in genomic sequenc-
ng studies as the first viral gene to encode distant
equence similarity to chemokines (Gompels et al.,
995). These proteins are proinflammatory cytokines that
an attract specific leukocyte subsets to a site of infec-
ion (Luster, 1998). Some chemokines can also inhibit
ertain strains of HIV via interactions with the chemokine
eceptors that act as HIV coreceptors with CD4 (Cairns
nd D’Souza, 1998). Thus expression of U83 may be
mportant to the specific biology of HHV-6. Other herpes-
iruses encode chemokine-like proteins. Human herpes-
irus 8 (HHV-8), the Kaposi’s sarcoma-associated her-
esvirus, encodes two chemokine homologues that can
nhibit HIV infection; at least one can bind chemokine
eceptors (Boshoff et al., 1997). Murine cytomegalovirus
ncodes a protein with sequence similarity to chemo-
ines and is expressed as a late gene (MacDonald et al.,
997). The temporal regulation of these chemokine-like
enes has important implications for the replicative cycle
f the virus in possible contributions to immune evasion
r participation in virus spread.
In this report, we investigate the expression of U83
nd show that it is regulated by novel splicing. The
esults show U83 is produced as two mRNA transcripts.
ne transcript corresponds to the full-length U83 gene,
hereas the other, more abundant message is inter-
upted by splicing, with an intron of 77 nucleotides ex-
ised and a stop codon introduced. We show that the
83 splice acceptor and donor sites do not conform to
urrently defined consensus sites. We demonstrate that
he novel splicing is not cell specific or virus dependent.
roduction and accumulation of the full-length transcript
o, however, appear to require a virus or virus-induced
omponent. Kinetics data are described illustrating the spliced transcript with characteristics of the IE class,
roduced in the absence of virus protein production,
hereas the unspliced U83 product is maximally pro-
uced late after virus DNA replication, similar to the
inetics shown for U22. The effects of strain variation are
ssessed in relation to the novel splicing. The results
how different levels of gene regulation for the produc-
ion of the viral chemokine-like protein and suggest the
xistence of a novel cellular mechanism for control of
ene expression.
RESULTS
he U83 gene is expressed as full-length and spliced
orms in HHV-6-infected cells
Comparisons between HHV-6 and the closely related
HV-7 show that there are homologues for most of the
enes. There are a few genes that are specific for HHV-6
hat encode properties distinct for this virus. U83 en-
odes a small chemokine-like protein (Gompels et al.,
995), one of HHV-6-specific genes that is diagnostic for
his virus. To examine the expression of this potentially
mportant gene in HHV-6, a series of reverse transcrip-
ion-polymerase chain reaction (RT-PCR) analyses were
ndertaken. Initially the prototype strain U1102 (variant A
train group) was used; then all results were repeated
sing strain CV as a B variant representative. The mRNA
ranscript was characterised by RT-PCR of poly(dT)-gen-
rated cDNA from U1102-infected JJhan (Jurkat clone,
-leukemic) cells 5 days p.i. The production of all cDNA
as monitored by amplification of the b-actin gene (data
ot shown). U83-specific primers, P7 and U83C, were
esigned from the HHV-6 genomic sequence (strain
1102) to amplify the entire coding sequence together
ith 59 and 39 untranslated regions, resulting in a 402-bp
roduct. However, the RT-PCR results showed only very
eak amplification of the 402-bp product (optimised in
ater kinetic studies described below) but strong ampli-
ication of a smaller product of ;300 bp (Fig. 1A). To
how this was not an artifact of a single primer set,
mplification of the U83 transcript was repeated using
urther U83 gene-specific primer pairs shown in Fig. 1
P6 and U83C, U83F2 and U83C, U83P1 and U83P2, and
83F and U83B). In all cases, a product, ;100 bp smaller
han expected from the DNA sequence, was preferen-
ially amplified (data not shown). To investigate whether
hese U83 mRNA transcripts were an aberration due to
he expression in a leukemic T cell line, identical exper-
ments were performed in primary cells [peripheral blood
ononuclear cells (PBMCs)]. Again, the smaller 300-bp
roduct was amplified in greater abundance compared
ith the expected 402-bp product (Fig. 1B). Thus the
mplification of the smaller U83 mRNA transcript is not
ependent on the cell type. Sequence analyses of the
maller RT-PCR products from the JJhan cells and the
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141NOVEL SPLICING/REGULATION IN VIRAL “CHEMOKINE”BMCs showed them to be spliced transcripts of U83,
rom which an intron of 77 bp had been excised (Fig. 2).
To detect the presence of full-length U83 only and not
he spliced U83 transcript, a 39 intron-specific primer
83INB) was designed. This allowed us to investigate the
resence and abundance of any full-length U83 mRNA
ranscript. The previous RT-PCR results (Fig. 1) show that
he full-length transcript, with an expected size of 402 bp,
s only just visible in the infected JJhan and PBMC sys-
ems. Amplification with the 59 primer, P7, and the 39
ntron-specific primer, U83INB, on identical cDNA re-
ulted in the full-length U83 transcript being amplified to
detectable level. An identical result was obtained using
he PBMC-generated cDNA (data not shown). Thus both
ull-length and spliced transcripts are expressed from
he U83 gene. Identical results were shown for strain CV
variant B strain group) giving a similar spliced product
nd are described further in the sequencing and kinetic
xperiments.
equence analyses of the U83 transcripts show novel
plice sites
The spliced and unspliced products were character-
sed further by sequence analyses. The RT-PCR products
rom all primer sets, external primers and intron primers,
ere gel-purified and cloned into pGEMRT, using TA
igation, followed by nucleotide sequencing. This
howed that both a full-length and a spliced polyadenyl-
ted transcript of U83 are present in HHV-6-infected
Jhan cells and PBMCs. The cDNA encoding the spliced
ranscript lacks an intron of 77 bp that occurs 121 bp from
he U83 ATG start codon, giving a 325-bp product (Fig. 2).
he sequence of the unspliced transcript is identical to
he published U83 DNA sequence (Gompels et al., 1995),
xcept for a CG inversion that resulted in a coding
FIG. 1. RT-PCR analysis of HHV-6 U83 from uninfected and U1102-
nfected cells. RT-PCR products generated using primers U83P7 and
83C, which amplify the whole U83 gene region from (A) infected JJhan
ells or (B) infected PBMCs. (C) RT-PCR products generated from
nfected JJhan cells, using primers U83P7 and U83INB, specific for the
ull-length transcript by using one intron primer. Lane 1, H2O negative
ontrol; lane 2, uninfected DNA; lane 3, U1102-infected DNA; lane 4,
2O negative control; lane 5, uninfected cDNA; lane 6, U1102-infected
DNA; and lane 7, H2O negative control. Sizes of products are in base
airs.hange (nucleotide 213, amino acids 71/72 DE to EQ); ohis was confirmed by direct sequencing of PCR prod-
cts from multiple stocks of U1102, including the earliest
assaged isolate. Similar splicing results were shown for
n HHV-6 variant B strain CV by nucleotide sequencing
f the spliced and full-length products (shown below).
The acceptor and donor splice sites utilised by the
83 intron do not conform to the consensus for the major
lass of introns, GT-AG (Fig. 3). The sites varied from
hese major class, U2-type, spliceosomal introns, which
ave the consensus of (with underlined invariant resi-
ues) AG^GURAGU for the donor and YAG^ for the ac-
eptor together with a preceding polypyrimidine tract
where Y is pyrimidine, R is purine, and ^ indicates the
plice site) (Mount, 1982; Stephens and Schneider, 1992;
ramer, 1996). Furthermore, the U83 splice sites also do
ot conform to the minor class, U12-type, of introns,
T-AC, which have recognition donor and acceptor con-
ensus of ^AUAUCUU and YCAC^ of U12-type introns
Hall and Padgett, 1994). Moreover, in U83 there is no
ecognisable branch site consensus for the minor splic-
ng class, UCCUUAAC, and only a weak match (TCAT-
AT) for the major class branch consensus of YNYURAY
N indicates any nucleotide) (Kramer, 1996) at 32 bp
pstream from the acceptor splice site (Fig. 2B). Given
hat this may be a novel type of intron, it is not possible
o predict the branch site. Even if the intron splicing was
ediated by U2 snRNA, it would be difficult to identify the
onserved adenine branchpoint for the major splice
lass given the overall adenine-rich nature of this area.
The exact location of the novel splice site in U83 is not
lear because both the donor and acceptor have a direct
epeat of TACC. This is similar to the repeated AGG
ounding some of the major class splice sites. Although
here is some similarity to features of both the major and
inor splicing classes, the splice sites in U83 are dis-
inct and do not conform easily to either grouping. Taking
he U83 splice preceding CT as the donor and AC in the
cceptor, these sites may represent a new minor class of
ntron, CT-AC.
apid amplification of cDNA ends analyses of the 39
nd of the U83 transcripts
The poly(A)1 site available downstream from the
83 ORF overlapped the next ORF, U84, a homolog of
spliced message in HCMV (Gompels et al., 1995).
herefore, rapid amplification of cDNA ends (RACE)
as used to examine whether this poly(A)1 site was
tilised or whether there was any further splicing at
he 39 end of the cDNA. A poly(dT) 39 primer was used
ogether with a 59 primer U83F2 to amplify a RACE
roduct from U1102-infected PBMCs. Sequence anal-
ses showed this product to be the unspliced tran-
cript of U83, again demonstrating its presence in a
olyadenylated form (Fig. 2). The 39 noncoding region
f the unspliced U83 cDNA was shown to end 12
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142 FRENCH ET AL.ases after a typical AATAAA polyadenylation signal,
49 nucleotides after the stop codon (Fig. 2). This
ndicates that the full-length U83 transcript uses the
irst polyadenylation site after the stop codon. Using
he poly(dT) primer, a smaller product was generated
hat corresponded to the size of the intron removal
ith no further differences (not shown). An element for
RNA degradation, TTATTTA, frequently found in the
9 noncoding regions of cytokines and chemokines
Lagnado et al., 1994) was found to precede the poly-
denylation signal, although it is unknown whether
his functions in the U83 transcript. Based on the RACE
FIG. 2. (A) Summary of the structure of the U83 spliced and unsp
espectively. AATAAA indicates the location of the polyadenylation sig
ndicated. The sizes of the transcripts from the start codons are indica
lso shown (kDa). The determined protein sequence after the intron re
pliced forms of transcript. Primers used in the analyses are indicated
pliced U83 transcripts. The predicted signal peptide cleavage poin
ermination codons are indicated by asterisks. The polyadenylation sig
umbered 1–4. The dashed line in the spliced protein sequence indicnalyses, there was no evidence of further splicing for the U83 ORF in addition to the novel splicing defined
bove.
he novel U83 splicing stops expression of an
ncoded chemokine-like protein
The full-length U83 mRNA transcript encodes a puta-
ive protein of 97 amino acids, 10.4 kDa in size, with a
ignal peptide sequence at the N-terminal end. The pu-
ative protein contains the characteristic four cysteine
esidues of b-chemokines (Fig. 2B) as described previ-
usly (Gompels et al., 1995). The two putative U83 pro-
anscripts. Open and shaded areas represent the exons and intron,
e locations of the ATG start codons and TGA termination codons are
); sizes of the encoded proteins (as determined by the sequence) are
indicated in single-letter amino acid codes for both the unspliced and
ws. (B) DNA and deduced amino acid sequence of the unspliced and
icated by a vertical line. The 77-bp intron sequence is underlined.
ouble-underlined. The chemokine-like signature cysteine residues are
e sequence has no interruptions.liced tr
nal. Th
ted (bp
gion is
by arro
t is ind
nal is deins are shown in Fig. 2B. In the spliced transcript, the
i
i
d
s
o
i
r
c
b
a
s
S
c
l
v
m
w
a
r
q
g
c
b
b
1
a
r
i
s
s
s
g
g
h
(
t
T
g
a
s
v
s
c
s
s
v
t
d
s
n
s
f
t
a
c
t
c
s
V
l
a
t
b ice con
143NOVEL SPLICING/REGULATION IN VIRAL “CHEMOKINE”ntron of 77 bp introduces a single-base frameshift, caus-
ng a coding change from serine to a valine, and intro-
ucing a TGA stop codon after two codons following the
plice acceptor site. This now encodes a shorter peptide
f only 42 amino acids, predicted to be 5 kDa in size but
dentical to the full-length U83 protein at its N-terminal
egion. The encoded spliced amino acid sequence now
ontains only two of the four conserved cysteines of the
-chemokine-like motif. To check whether this was an
berration of the prototype strains analysed, the coding
equences of 16 strains were examined.
equence analyses of strains show high variation but
onserved novel splice sites
Comparisons between amino acid sequences pub-
ished for HHV-6 prototype variant A strain (U1102) and
ariant B strain (Z29) show relatively high variation (13%),
ostly in the first three fourths of the sequence. To check
hether the novel splicing identified in U83 was not just
n aberration of the strains analysed, we examined this
egion in 16 strains by PCR followed by nucleotide se-
uencing and multiple alignments (Fig. 4). Included were
eneral laboratory reference strains, U1102, Z29, and CV,
ompared with strains identified in clinical isolates and
iopsies from pediatric patients. These strains were from
oth variant A and B classes of HHV-6 (Gompels et al.,
993; Kasolo et al., 1997). The results confirm up to 10%
nd 13% nucleotide and amino acid sequence variation,
espectively, between all the strains in pairwise compar-
sons, with up to 3% variation within the variant A or B
train groupings (Figs. 4 and 5). In contrast to U83,
imilar analyses of the other HHV-6-specific gene, U22,
howed conservation between strains from both variant
FIG. 3. Splicing sites do not conform to consensus. (A) Comparisons
y Staden (1991) for use in the Nip program for the major class of splroups with ,5% variation, a level previously shown for tenes such as glycoprotein H that are conserved in
erpesviruses rather than specific for an individual virus
not shown) (Gompels et al., 1993).
Despite the relatively high level of variation in U83 for
his herpesvirus, the novel splice sites are conserved.
here is only one base change at position 200 (C to T,
roups A and B, respectively) in the splice acceptor,
lthough this does not appear to affect the splicing as
hown by the sequence of the spliced product of the
ariant B CV strain. Interestingly, there are upstream
ites that show some matches to the major class donor
onsensus and only weak acceptor consensus down-
tream. The major class donor sites are weakened in the
train variants (Fig. 4). In contrast, in the strains from B
ariants, the novel splice duplication TACC is extended
o TACCTG (Fig. 6). Between the strains, there was ad-
itional variation in sequence and length in the 59 up-
tream region; however, this was strain specific and did
ot correlate with the variant A or B grouping (data not
hown). Analyses of the encoded amino acid sequence
rom the strain variants showed high amino acid varia-
ion but conservation of the b-chemokine-like motifs and
djoining sequences (Fig. 5). Moreover, in all strains, the
onserved splice introduces a stop codon that interrupts
he encoded chemokine-like protein between the crucial
onserved cysteines and divides it into a truncated, pos-
ibly nonfunctional peptide (Fig. 5).
irus regulation of U83 spliced as an IE gene and full
ength as a late gene
Having demonstrated expression of both full-length
nd novel spliced versions of U83 and conservation of
he splice sites in the strain groups, we next examined
atrix based on Mount’s (1982) catalog of major class sites as adapted
sensus. Sites are shown for U1102 (variant A) and CV (variant B).with a mhe kinetics of their expression. Herpesvirus genes
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144 FRENCH ET AL.an be classified into three kinetic groups of expres-
ion: IE, which are produced without de novo protein
ynthesis [resistant to cycloheximide (CEX)]; early
enes, which are regulated by the expression of IE
enes; and late genes, which are those expressed
fter DNA replication [sensitive to phosphonoacetic
FIG. 4. Multiple alignments of 14 HHV-6 strains show conservation of
LUSTALV program (Higgens algorithm) as implemented on a Macinto
ndicated by underlining the conserved GT, and the TACC repeats of t
FIG. 5. Analyses of strain variation and coding sequence in relation
ntroduction of a stop codon as the resulting encoded truncated peptid
omparison of A and B variant strains with HHV-8 Mip1 homolog and
dentical or similar (uppercase and lowercase) residues in U83 to ch
onsensus. Splicing stop and termination codons are indicated by aste
U1102). Strains analysed in Fig. 3 conform to A and B variants shown
BE, and HT; HHV-6B strains CV, BOU, Z3, Z12, Z13, Z14, Z25, and Z31
1102 and Z27. HHV-6A strains Z23 and Z59 also have P46 to S and M
HV-6A strain Z59 also has M55 to L.cid (PAA)]. Northern blot analyses of poly(A)1-se-
ected RNA showed IE expression of the U83 tran-
cript. There was insufficient resolution at this size to
ifferentiate expression of the spliced and unspliced
roducts. To examine this in further detail, the kinetics
f the full-length and spliced transcripts of U83 were
splice sites. Alignment of the first 210 bases of the U83 gene using the
puter. Major site donor sites predicted using the Staden program are
l splice donor and acceptor in actual use are also underlined.
novel splicing. The splicing regulates chemokine expression via the
rupts the chemokine consensus; this is shown in all strains analysed.
e CC and CXC chemokines, Rantes and interleukin-8. CON indicates
es. Conserved chemokine signature cysteines are underlined in the
83 strain variations are underlined in U83B (Z29) compared with U83A
inor additional variation as follows: HHV-6 B shown is for strains Z29,
have L27 to S; and strain CV also has S23 to F. HHV-6A is for strains
I. HHV-6A Z5 also has A53 to E. HHV-6A strain Z23 also has I54 to V.novel
sh comto the
e inter
prototyp
emokin
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145NOVEL SPLICING/REGULATION IN VIRAL “CHEMOKINE”hen analysed using RT-PCR of cDNA generated from
train U1102- (variant A) and CV- (variant B) infected
Jhan cells. Conditions were those established to de-
ine IE and late genes of HHV-6 as described previ-
usly (Mirandola et al., 1998).
Figure 6 shows that both U83 transcripts occur early in
nfection and that neither transcript is inhibited by CEX,
upporting grouping in the IE kinetic class. The spliced
ranscript (304 bp) is unaffected by the inhibitors CEX
nd PAA, suggesting regulation as an IE or E gene.
urprisingly, the full-length U83 transcript accumulated
o higher levels at 16–40 h p.i. (Fig. 6A). This can be seen
ith greater clarity when the transcript is amplified using
he same 59 primer together with a 39 intron-specific
rimer U83INB, which detects only the full-length tran-
cript (Fig. 6C). The increase was reduced by blocking
NA replication with the inhibitor PAA. Comparisons
ere made with the other HHV-6-specific gene, U22. This
ad the kinetics of a true late gene in HHV-6, that is, a
ene that is expressed at late times p.i. and is dependent
n virus DNA replication for expression. U22 could be
mplified at 40 h p.i. only, and its transcript was inhibited
y PAA (Fig. 6D). No evidence for splicing of U22 was
FIG. 6. Kinetics of expression for U83 RNA transcripts. (A) Strain
1102 RT-PCR products generated using U83 primers, U83–1 and
83–2, which amplify the entire U83 gene region. (B) As in A but using
train CV-infected cells. (C) Strain U1102 RT-PCR products generated
sing primers, U83–1 and U83INB, which are specific for the full-length
ranscript using one intron-specific primer; identical results were ob-
ained with strain CV. (D) RT-PCR products generated using the U22
rimers. RNA was isolated in the absence of inhibitors (lanes 3–7), and
n the presence of CEX (lanes 8–10) and PAA (lanes 11 and 12). Lane 1,
2O negative control; lane 2, U1102-infected DNA; lanes 3–12, HHV-6-
nfected cDNA at various time points p.i.; lanes 3 and 8, 3 h; lanes 4 and
, 6 h; lanes 5 and 10, 8 h; lanes 6 and 11, 16 h; and lanes 7 and 12, 40 h.
izes of products are indicated in base pairs.ound by RACE and cDNA sequence analyses. Further- uore, in the absence of RT, no PCR product was ob-
ained, indicating that the kinetics was due to RNA tran-
cripts and not to DNA contamination, which may be
ntroduced after the increased virus DNA replication at
ate times p.i. Thus the overall RT-PCR analysis demon-
trated that the U83 spliced transcript displays some
haracteristics of IE kinetics, whereas the full-length
ranscript displays dual kinetics involving both early and
ate phases of infection. Similar results were obtained
sing the variant B strain CV, although the full length
ccumulated at later times (40 h), which was reduced by
AA (Fig. 6B). This may reflect a delayed replicative cycle
r differing sensitivities to PAA. For all primer sets, no
alse-positive amplification was detected in uninfected
ells or in the cell-free virus innoculum. Spliced products
f U1102 and CV strains were confirmed by sequence
nalyses. These results indicated that the novel splice
an be performed in the absence of virus protein pro-
uction (CEX case), whereas the full-length product re-
uires virus replication for maximal expression.
83 novel splicing in a stably expressing cell line
Because the spliced product was expressed as an IE
ene in the absence of virus protein expression, this
esult indicated that the novel splice can be recognised
y cellular mechanisms. To further investigate this, a
table U83-expressing cell line was produced. The full-
ength U1102 U83 gene was amplified by PCR using
rimers U83P1 and U83P2, purified, and cloned into the
ukaryotic expression vector pCDNA3, forming the con-
truct pCDNA3-U83. This construct was transfected into
he parental cell line and selected using G418. The ex-
ernal gene-specific primers used earlier were outside of
he coding sequence amplified here, so internal U83
rimers U83F2 and U83B2 were designed for RT-PCR
mplification in the U83 cell line. Amplification of the cell
ine DNA resulted in a 233-bp product, whereas amplifi-
ation of the cell line cDNA produced a band with re-
FIG. 7. U83 splicing in stable cell lines. (A) RT-PCR products gener-
ted using primers, U83F2 and U83B2, which amplify an internal por-
ion of U83 and are designed to detect both spliced and unspliced
roducts. (B) RT-PCR products using primers U83F2 and U83INB, de-
igned to detect only the full-length transcript. Lane 1, H2O negative
ontrol; lane 2, U1102-infected DNA; lane 3, HaCaT U83 DNA; lane 4,
aCaT U83 cDNA prepared without reverse transcriptase; and lane 5,
aCaT U83 cDNA prepared with reverse transcriptase. Sizes of prod-
cts are in base pairs.
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146 FRENCH ET AL.uced size, 156 bp, that corresponded to the spliced
roduct in infected cells (Fig. 7A). However, under the
onditions used here, the unspliced product was not
etectable even using the intron primer (Fig. 7B) or two
ntron-specific primers (not shown). The RT-PCR product
as gel-purified, and sequence analyses showed a
pliced transcript of U83 identical to the spliced tran-
cript in the infected JJhan cells and PBMCs (Fig. 2). This
esult demonstrates that there is recognition of the novel
83 splice donor and acceptor sites by cellular mecha-
isms in the absence of the virus, thus confirming the IE
inetic data that showed splicing in the absence of virus
rotein synthesis. It also shows that the splicing of U83
s not dependent on other viral factors or additional viral
NA components that are not included in the pCDNA3-
83 construct. Thus the novel cellular splicing stops
xpression of the encoded chemokine-like protein and
irus regulation of this splicing allows the expression.
FIG. 8. In vitro transcription translation of U83 full-length and spliced
enes. Lane 1 shows translated full-length U83; lane 2, spliced U83;
ane 3, reverse orientation gene negative control; and lane 4, plasmid
ector pCDNA3. Low-molecular-weight markers are indicated with
izes in kDa in lane M. The apparent molecular masses of translated
ull-length and spliced U83 are indicated as 10.4 and 5.5 kDa, respec-
ively.
FIG. 9. Immunofluorescence staining of U83 MAb on HHV-6 strain U
ontrol MAb 2E4 specific for HHV-6 gH on acetone-fixed infected cells
or HHV-6 U83. (C) Negative control staining with MAb 52s specific for H
ere observed against uninfected cells with these MAbs.n vitro transcription translation analyses and
mmunofluorescence detection in infected cells
The full-length gene and spliced U83 cDNA were
loned in an expression vector and examined for protein
xpression. In vitro transcription translation showed that
he full-length and spliced transcripts translated into
0.4- and 5.5-kDa proteins similar to the predicted mo-
ecular masses (Fig. 8). There was no evidence for RNA
elf-splicing in this system because the full-length tran-
cribed product translated only into the predicted 10.4-
Da protein species. In studies to be described else-
here, a GST U83 fusion protein was used to immunise
ice, and a monoclonal antibody (MAb), FC2, was iso-
ated from hybridoma cells using methods previously
escribed (Liu et al., 1993b). This antibody showed no
eactivity to GST by immunoblotting and was specific for
he fusion protein. In infected cells, the MAb was effec-
ive in immunofluorescence assays. Figure 9 shows spe-
ific reactivity to strain U1102-infected JJhan cells. In
omparison with staining with HHV-6 gH MAb, the U83
Ab showed more diffuse cytoplasmic distribution with
ome evidence for surface capping as observed for gH.
ositive immunofluorescence was observed 3–5 days
.i. with no reactivity to uninfected cells and no specific
eactivity to the cell lines where only the spliced gene
as detected. This supports the transcriptional analyses
hat show the gene is expressed during infection in
issue culture and indicates that protein levels are de-
ectable at late times p.i., which would be consistent with
roduction of the full-length transcript.
DISCUSSION
Novel splicing is demonstrated in the HHV-6-specific
ene U83. Both in-frame full-length and spliced products
re produced. The spliced product encodes a truncation
f the full-length product. The splice is reproduced in a
83-expressing cell line, showing that this splicing can
fected JJhan cells. (A) Infected cells at day 4 p.i. stained with positive
ribed previously (Liu et al., 1993b). (B) Staining with MAb FC2 specific
(ATCC) (Gompels et al., 1991). Using identical conditions, no reactions1102-in
as desc
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147NOVEL SPLICING/REGULATION IN VIRAL “CHEMOKINE”e cell mediated in the absence of other viral products.
t is possible that this is also a new form of self-splicing,
ut the intron does not superficially resemble group I or
I introns. Furthermore, T7 RNA polymerase-based in
itro transcription-coupled translation of the full-length
ene translates only the complete full-length protein. The
maller product of the spliced gene can be detected only
rom in vitro transcription translation of cloned cDNA of
he spliced transcript. The sites mediating the intron
plicing appear to be novel and do not conform to major
r minor class consensus sites for spliceosomal medi-
ted mammalian mRNA splicing (Kramer, 1996). More-
ver, the intron does not resemble the HAC1/ERN4
RNA required for unconventional splicing involving
RNA ligase and Ire1p/Ern1p endonuclease in the un-
olded protein response (Sidrauski and Walter, 1997;
awahara et al., 1998). In addition, given the conserva-
ion of sequences at the 59 and 39 splice sites and within
trains, this suggests a different mode from tRNA splic-
ng where sites are not conserved and tRNA splicing
ndonucleases measure from positions within the body
f the mature RNA (Trotta et al., 1997).
The U83 intron is bounded by a novel duplication
ACC, which is extended in strain B variants to TACCTG.
he existence of a duplication at these sites bears some
esemblance to the AGG motif often duplicated at major
plice junctions. If cleavage occurs in the same positions
f the ACC motif as in the AGG motif (Fig. 3), then the U83
ntron may represent a new minor class, CT-AC, in con-
rast to the major, GT-AG, and minor, AT-AC, spliceoso-
al classes. Alternatively, the duplication may suggest
he use of a specific endonuclease. Recent results show
he minor spliceosomal class may also use GT donors
Dietrich et al., 1997), but the U83 splice sites still do not
onform easily to this grouping. The major and minor
lasses use overlapping and distinct sets of snRNA mol-
cules to mediate splicing to form similar spliceosomal
achinery with differing specificity (Nilsen, 1996; Tarn
nd Steitz, 1996). Differences in base pairing with U11
nd U12 snRNA, in particular, differentiate the minor
lass from U1- and U2-associated major class, and pre-
ictions were made on the basis of sequence compari-
ons (Hall and Padgett, 1994). In U83, these comparisons
how that this intron does not fall easily into either group,
ossibly weak interactions are mediated by splicing en-
ancers and protein interactions, or this is a new class of
plicing.
Studies presented here of the kinetics of expression of
83 suggest virus infection and replication affects this
ovel splicing in HHV-6 U83. In cells, only the spliced
orm could be detected. In virus-infected cells, both the
ull-length and spliced products are made with IE kinet-
cs in the presence of translation inhibitor (CEX). The
ull-length product also further accumulated at late times
.i., and this accumulation was prevented using an in-
ibitor of virus DNA replication (PAA). In comparison, the eHV-6-specific gene U22 expressed only as a complete
rue-late gene, with expression dependent on virus DNA
eplication. Lack of the U83 full-length product in the cell
ine could also be due to differences in turnover or in the
9 and 39 untranslated regions in the cell-expressing
onstruct, which lack, in particular, the 39 AT-rich motifs
ound here in U83 and shown in other chemokine genes
o regulate mRNA turnover (Lagnado et al., 1994). Evi-
ence for dual kinetics for different spliced transcripts
rom the same gene has also been shown for another
HV-6 IE gene, U91 (Mirandola et al., 1998).
Viruses have been used as tools to investigate spli-
eosomal machinery and have shown roles for interac-
ions between major and minor class introns in modula-
ion of splicing efficiency. This is a cooperative mecha-
ism involving many different components, including
plice sites, intronic and exonic RNA sequences,
nRNAs, snRNPs, and SR proteins, as reviewed by
ramer (1996). Studies have shown that SR proteins and
nhancer elements, often purine-rich elements (PREs),
articipate in splicing regulation (Manley and Tacke,
996). HSV has been shown to alter the activity or dis-
ribution of SR proteins (Martin et al., 1984), and noncon-
ensus splice donors (GC) have been identified in la-
ency transcripts that can be involved in alternative
pliced transcripts (Spivack et al., 1991; Sandri-Goldin et
l., 1995). There are numerous examples of sequences in
oth introns and exons that act to inhibit or promote
plicing (Cote et al., 1992; McNally and Beemon, 1992;
mendt et al., 1994, 1995; Tanaka et al., 1994; Zhao et al.,
994; Staffa and Cochrane, 1995). Regulation sequences,
uch as PREs, are frequently associated with suboptimal
9 splice sites, such as those seen in U83. Moreover, the
xon-splicing silencer element of the HIV-1 tat-rev exon
as able to efficiently inhibit splicing in conjunction with
uboptimal 39 splice sites, such as itself and the Rous
arcoma virus src, but not with consensus splice sites
hat occur in the b-globin intron and the fibronectin gene
Amendt et al., 1994; Staffa and Cochrane, 1995). Splicing
nhancer elements and SR proteins of the adenovirus L1
nit have been shown to act as negative regulators of the
lternative 39 IIIa splice site by inhibiting the recruitment
f the U2 small nuclear ribonucleoprotein particle where
he position of the PRE in relation to the 39 splice site
etermines whether the enhancer acts positively or neg-
tively (Kanopka et al., 1996). It has recently been dem-
nstrated that the E4-ORF4 adenovirus protein is respon-
ible for regulating the shift in L1 alternative splicing at
he late phase of virus infection (Kanopka et al., 1998).
his involved an E4-ORF4-kinase complex in the dephos-
horylation of SR proteins, which prevented the inhibi-
ory effect and allowed splicing at the distal IIIa splice
ite. In vitro studies have also shown that protein kinases
re capable of directly inhibiting splicing (Gul et al.,
994). Recent data show that in a retrovirus, an enhanc-
r-like PRE sequence is a component of a splicing in-
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148 FRENCH ET AL.ibitor element (McNally and McNally, 1998). It is postu-
ated that this control involves interaction between major
nd minor splice sites. It is possible that such a scenario
ay apply to HHV-6 U83 in that there are predicted 59
ajor donor sites that are not utilised and the entire
ntron is purine rich, which may resemble a PRE. Analy-
es of the HHV-6 genome sequence identified three
otential SR proteins, U86, DR8, and DR1 (Gompels et al.,
995), and they may participate in such control of RNA
rocessing efficiency.
The splicing in U83 regulates expression of the che-
okine-like protein by introducing a termination codon
hat stops expression of the protein encoded by the
ull-length transcript. The splicing seems to be efficient
nd functioning before the expression of any virus pro-
eins (CEX treatment). Although U83 is relatively variable
13%) between HHV-6 strains, the novel splice site is
onserved. The high variation in U83 is interesting in that
he adjacent genes, such as glycoprotein gL, are con-
erved and that there is a high proportion of coding
hanges in U83 indicative of some selection, possibly
mmune driven or via different ligand–receptor interac-
ions. However, splicing efficiency and the structures of
oth the full-length and truncated U83 protein, produced
y a spliced stop codon, are all conserved between
trains. This seems to be a general mechanism for the
ontrol of this HHV-6-specific gene product using a cel-
ular splicing pathway. HHV-6 infects cells of hemapoi-
tic origin; thus the chemokine-like U83 protein may
ffect virus spread in mediating an inflammatory re-
ponse that could be critical to lytic or latent infections
y this virus. In another herpesvirus, murine cytomega-
ovirus, which also encodes a protein with chemokine
equence similarity, the transcript is regulated as a late
ene (MacDonald et al., 1997). In HHV-6, the full-length
83 is also regulated as a late gene, whereas the
pliced and interrupted transcript has characteristics of
n IE gene. The truncated peptide encoded in the spliced
essage interrupts the similarity with the chemokine
amily.
In summary, U83 shows novel splicing that can be
ccomplished in cells but can be affected by virus infec-
ion. The splicing regulates expression of the encoded
hemokine-like protein by introducing a spliced stop
odon interrupting the gene, whereas the full-length
roduct is observed only after virus infection and repli-
ation. This novel regulation of HHV-6 U83 may also
ndicate a distinct pathway for cellular control of gene
xpression.
MATERIALS AND METHODS
ells and virus
The CD41 T lymphocyte cell line JJhan (Jurkat clone,
-leukemic) and PBMCs were grown in suspension cul-ure at 37°C in RPMI containing 2 mM glutamine, 100 i/ml penicillin, 100 mg/ml streptomycin, and 10% (v/v)
CS. Viral cultures were prepared through infection of
Jhan cells or PBMCs with HHV-6 strain U1102, variant A
Gompels et al., 1995), or CV, variant B, as described
reviously (Mirandola et al., 1998). HaCaT human epithe-
ial cell lines were grown in monolayers, in identical
edia, and derived transfectants were cultured with the
ddition of 500 mg/ml G418. Cellular and viral DNA were
xtracted from 5-day-old cultures using a proteinase
–SDS, phenol–chloroform extraction procedure.
CR analysis of DNA
Isolation of DNA from HHV-6-positive Zambian patient
amples has been described by one of our groups pre-
iously (Kasolo et al., 1997); the DNA was kindly donated
y F. C. Kasolo (University Teaching Hospital, Zambia;
ondon School of Hygiene and Tropical Medicine, UK).
29 DNA was kindly provided by Prof. G. Campadelli-
iume (University of Bologna, Bologna, Italy). Sample
NA was amplified for the U83 gene using primers
83P6 (59-ACAAATAGTAAAGGATCCATGGTT-39) and
83B (59-CGACAATCCTAATTCAAGAC-39). PCR was car-
ied out under standard conditions with 1.5 U of Taq
olymerase and buffer (Promega, Madison, WI), 1 mM
oncentration of the primers, 200 mM concentration of
he dNTPs, and 1.5 mM MgCl2 in a total volume of 29 ml
ith 1 ml of template or control DNA. The thermocycling
rocedure was 30 cycles of denaturing at 94°C for 1 min,
nnealing at 50°C for 1 min, and extension at 72°C for 1
in. Each run contained a reagent (water), negative
ontrol (uninfected JJhan cellular DNA), and positive con-
rol (U1102-infected JJhan cellular DNA or plasmid
CDNA3-U83 DNA). The PCR products were resolved
nd detected visually by 2.0% agarose gel electrophore-
is with ethidium bromide staining.
T-PCR analysis of RNA
Cells from confluent cultures were washed twice in
terile PBS. Total cellular RNA was extracted using RNA
solator (Genosys, Cambridge, UK), where the RNA pellet
rom 10 ml of starting culture was resuspended in a total
olume of 50 ml. For each sample, a 25-ml aliquot was
tored at 280°C, and the remainder was treated with 2.5
of DNase RQ1 (Promega) to remove residual DNA
efore first-strand cDNA synthesis. First-strand cDNA
ynthesis was performed as follows: 2 mg of total RNA
nd 1 mM poly(dT) adapter primer (GIBCO BRL, Gaith-
rsburg, MD) in a final volume of 11 ml was incubated at
5°C for 10 min, followed by 10 min on ice. This RNA was
everse transcribed in a final volume of 50 ml containing
0 U of Moloney murine leukaemia virus RT (Promega),
0 mM dithiothreitol, 500 mM dNTP, and 40 U of RNasin
nhibitor (Promega) for 1 h at 37°C, followed by 10 min on
ce. The cDNA was amplified by PCR under standard
c
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149NOVEL SPLICING/REGULATION IN VIRAL “CHEMOKINE”onditions (see PCR analysis of DNA), using 5 ml cDNA
emplate and gene-specific primers for U83: U83P7 (59-
CGGGATCCACATCTTATATATAG-39) with U83C (59-TA-
TGTCTTCTAGATACTTTC-39) or U83F2 (59-CCCCGAT-
CGGAGCTGTTTTCC-39) with U83B2 (59-CAAGACTT-
TCGGCGATGCATC-39).
In addition, F2 was used with an intron-specific 39
rimer, U83INB (59-GGTAAGCAGCAGAACAAC-39).
Actin primers were used as internal controls: actin-F
59-GATGGAGTTGAAGGTAGTTT-39) and actin-B (59-TGC-
ATCCAGGCTGTGCTAT-39).
All samples were checked for DNA contamination and
ere PCR negative in the absence of RT. RACE was
erformed under standard conditions for 40 cycles, using
ml sscDNA template and the gene-specific primer
U83F2) with the poly(dT) adapter primer (GIBCO BRL). A
ositive control for the 39 RACE reaction was performed
sing control RNA obtained from GIBCO BRL. PCR prod-
cts were separated by 2% agarose electrophoresis and
isualised by ethidium bromide staining. cDNA was gel
urified using GeneClean (Anachem) and either se-
uenced directly or cloned into the TA cloning vector
GEMR-T (Promega) before sequencing.
NA sequencing
HHV-6 DNA PCR products were gel purified using
eneClean. Plasmid DNA of clones were prepared using
V Wizard preps (Promega). Sequencing reactions were
arried out using the ABI Prism Dye terminator cycle
equencing ready reaction kit (Perkin–Elmer Cetus, Nor-
alk, CT). DNA was sequenced on the ABI Prism 377
equencer (Perkin–Elmer).
inetics of expression
Time course infection and metabolic inhibition studies
ith CEX, to inhibit protein synthesis, and PAA, to inhibit
iral DNA replication, were done essentially as de-
cribed before using both strains U1102 (HHV-6 variant
) and CV (HHV-6 variant B) (Mirandola et al., 1998).
ell-free virus was used to inoculate cell cultures, and
NA was harvested at intervals p.i. in the presence or
bsence of CEX or PAA acid treatment as described
reviously (Mirandola et al., 1998). RT-PCR analyses
ere performed using reverse-transcribed poly(A)1-se-
ected mRNA with random hexamer primers to generate
DNA followed by PCR with the following primers for
83, detecting full-length and spliced products 83–1 (59-
GGCATATATTGGTATGGCT-39) and 83–2 (59-TTG-
TCTCTTTGCGTCTTCT-39); for the full-length product
rimer 83–1 together with the intron-specific primer
83INB (as above); and for gene U22, 22–1 (59-GTGAT-
ATGGTGCCTCAGGG-39) and 22–2 (59-GATCGCCGT-
ATACCACAAC-39). Ponstruction of U83 expressing cell line
The U83 gene was amplified using PCR with standard
hermocycling procedures and Taq polymerase (Pro-
ega). The following primer set was used to amplify the
oding region and to introduce BamHI restriction enzyme
ecognition sequences: U83P1 (59-ACGGGATCCATTGG-
ATGGCT-39) and U83P2 (59-TTCGGATCCTTTCATGAT-
CT-39). The product amplified was then digested with
amHI restriction enzyme, separated by agarose gel
lectrophoresis, and purified by phenol extraction fol-
owed by ethanol precipitation. The purified DNA was
igated with BamHI-digested, alkaline phosphatase-
reated (Boehringer-Mannheim Biochemica, Mannheim,
ermany) plasmid pCDNA3 (InVitrogen, San Diego, CA)
nd transformed into Escherichia coli strain JM109. The
elected clone was checked by sequence analyses in
omparison with published sequence and separately
mplified products from infected cell DNA. The plasmid
ith the gene oriented for expression from the CMV
romoter was designated pCDNA3-U83. Both vector-
nly, pCDNA3, or U83 cloned DNA, pCDNA3-U83, were
sed to transfect human epithelial cells (HaCaT) using
ipofectin (Life Technologies, Eggenstein, Germany) ac-
ording to the manufacturer’s instructions. Expressing
olonies were selected and grown using culture media
RPMI, 10% FCS with supplements as above) with 500
g/ml G418 (GIBCO BRL). Colonies were cloned using
erspex rings and analysed using the SP6 and T7 prim-
rs to amplify across the multiple cloning site in DNA
CR; expression was confirmed using RT-PCR and spe-
ific primers. Sequence analyses showed conservation
f the U83 sequence.
n vitro transcription translation analyses
The cDNA from the spliced U83 was similarly cloned
s described above by ligation with the pCDNA3 plasmid
ector. E. coli JM109 was transformed with either the
ull-length and spliced U83 plasmids and DNA prepared
sing Quiagen minipreps. In vitro transcription and trans-
ation was performed using the TNT Coupled Rabbit
eticulocyte Lysate system (Promega) according to the
anufacturer’s instructions. Briefly, 0.5 mg of plasmid
NA was used in an in vitro transcription and translation
ix containing 12.5 ml of rabbit reticulocyte lysate, 20 U
f RNasin, 15 mCi of 35S-methionine (SJ1515; Amersham
orp., Paisley, UK), and 7.5 U of T7 RNA polymerase.
eactions conditions used were 30°C for 90 min, fol-
owed by separation of translated products on SDS–
AGE with 18% acrylamide gels (Novex, San Diego, CA).
mmunofluorescence
As described previously (Liu et al., 1993a), U1102-
nfected JJhan cells were fixed with acetone, washed in
BS, blocked with neat FCS, reacted with monoclonal
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150 FRENCH ET AL.ntibodies for 30 min at 37°C, further washed in PBS,
nd then reacted with fluorescein isothiocyanate conju-
ated to rabbit anti-mouse IgG (1:200; Sigma Chemical
o., St. Louis, MO) for 30 min at 37°C. After PBS washes,
he cells were examined by fluorescence microscopy
ith 4003 magnification and 450/410-nm wavelength.
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